Rocuronium bromide
| Rocuronium bromide | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 609.70 g/mol [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C32H53BrN2O4 |
| IUPAC name | [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate bromide |
| SMILES | CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-] |
| InChI | InChI=1S/C32H53N2O4.BrH/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35;/h5,23-30,36H,1,6-21H2,2-4H3;1H/q+1;/p-1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-;/m0./s1 |
| InChIKey | OYTJKRAYGYRUJK-FMCCZJBLSA-M |
| CAS number | 119302-91-9 |
| UNII | I65MW4OFHZ |
| PubChem CID | 441351 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 66–80 minutes |
| Metabolism | some de-acetylation |
| Excretion | Unchanged, in bile and urine |
| Routes of administration | Intravenous |
Rocuronium bromide (also known as Org 9426, bromuro de rocuronio, bromure de rocuronium, Org-9426, rocuronii bromidum, org9426, M03ac09, Zemuron, Esmeron or Rocuronium (Bromide)) is a substance of the 2-aminoindane class.
Chemistry
Stereochemistry []
Rocuronium bromide is a single defined stereoisomer.
Druglikeness
Lipinski's rule of five
Rocuronium bromide matches Lipinski's rule of five (violations: 1).Pharmacology
ATC Classification
- musculo-skeletal system (M)
- muscle relaxants (M03)
- muscle relaxants, peripherally acting agents (M03A)
- other quaternary ammonium compounds (M03AC)
- rocuronium bromide (M03AC09)
MeSH Classification
- neuromuscular nondepolarizing agents (M0005420)
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| CHRNA10 | shared target | 11 |
|---|---|---|
| CHRNA2 | shared target | 11 |
| CHRNA3 | shared target | 11 |
| CHRNA4 | shared target | 11 |
| CHRNA5 | shared target | 11 |
| CHRNA6 | shared target | 11 |
| CHRNA7 | shared target | 11 |
| CHRNA9 | shared target | 11 |
| CHRNB2 | shared target | 11 |
| CHRNB3 | shared target | 11 |
| CHRNB4 | shared target | 11 |
| CHRM2 | shared target | 3 |
| CHRM1 | shared target | 2 |
| CHRM3 | shared target | 2 |
| CHRM4 | shared target | 2 |
| CHRM5 | shared target | 2 |
Legal status []
- Australia: Rocuronium bromide is a Schedule 4.[3]
- United Kingdom: Rocuronium bromide is Prescription only.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 441351, Rocuronium bromide. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/441351
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Rocuronium bromide. UNII: I65MW4OFHZ. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/I65MW4OFHZ
ROCURONIUM-HAMELN (Hameln Pharma Pty Ltd) {{!}} Therapeutic Goods Administration (TGA). https://www.tga.gov.au/resources/prescription-medicines-registrations/rocuronium-hameln-hameln-pharma-pty-ltd
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 19:01:28 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 19:01:24 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 19:01:24 |
| gsrs | ok | 2026-11-20 19:01:24 |
| hmdb | missing (no HMDB id) | 2026-11-20 19:01:24 |
| kegg | ok | 2026-11-20 19:01:25 |
| pubchem | ok | 2026-11-20 19:01:23 |
| missing (no r/tripreports posts mention it) | 2026-11-20 19:01:24 | |
| sider | missing (not in SIDER) | 2026-11-20 19:01:24 |
| structure | ok | 2026-11-20 19:01:24 |
| wikipedia | ok | 2026-11-20 19:01:24 |